183 related articles for article (PubMed ID: 12023427)
21. Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy: a new American case.
Marzewski DJ; Towfighi J; Harrington MG; Merril CR; Brown P
Neurology; 1988 Jul; 38(7):1131-3. PubMed ID: 3290703
[TBL] [Abstract][Full Text] [Related]
22. [Creutzfeldt-Jakob disease in 4 children treated with growth hormone].
Billette de Villemeur T; Gourmelen M; Beauvais P; Rodriguez D; Vaudour G; Deslys JP; Dormont D; Richard P; Richardet JM
Rev Neurol (Paris); 1992; 148(5):328-34. PubMed ID: 1448646
[TBL] [Abstract][Full Text] [Related]
23. Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology.
Duyckaerts C; Sazdovitch V; Ando K; Seilhean D; Privat N; Yilmaz Z; Peckeu L; Amar E; Comoy E; Maceski A; Lehmann S; Brion JP; Brandel JP; Haïk S
Acta Neuropathol; 2018 Feb; 135(2):201-212. PubMed ID: 29209767
[TBL] [Abstract][Full Text] [Related]
24. Iatrogenic Creutzfeldt-Jakob disease via surgical instruments.
Thomas JG; Chenoweth CE; Sullivan SE
J Clin Neurosci; 2013 Sep; 20(9):1207-12. PubMed ID: 23896549
[TBL] [Abstract][Full Text] [Related]
25. Creutzfeldt-Jakob disease.
de Villemeur TB
Handb Clin Neurol; 2013; 112():1191-3. PubMed ID: 23622328
[TBL] [Abstract][Full Text] [Related]
26. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.
Abrams JY; Schonberger LB; Belay ED; Maddox RA; Leschek EW; Mills JL; Wysowski DK; Fradkin JE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1666-9. PubMed ID: 21816775
[TBL] [Abstract][Full Text] [Related]
27. Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment.
Cordery RJ; Hall M; Cipolotti L; Al-Sarraj S; O'Donovan DG; Davidson L; Adlard P; Rossor MN
J Neurol Neurosurg Psychiatry; 2003 Oct; 74(10):1412-6. PubMed ID: 14570836
[TBL] [Abstract][Full Text] [Related]
28. Iatrogenic Creutzfeldt-Jakob disease subsequent to dural graft: persisting risk after 1987.
Boutoleau C; Guillon B; Martinez F; Vercelletto M; Faure A; Fève JR
Eur J Neurol; 2003 Sep; 10(5):521-3. PubMed ID: 12940833
[TBL] [Abstract][Full Text] [Related]
29. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.
Swerdlow AJ; Higgins CD; Adlard P; Jones ME; Preece MA
Neurology; 2003 Sep; 61(6):783-91. PubMed ID: 14504321
[TBL] [Abstract][Full Text] [Related]
30. Creutzfeldt-Jakob disease after administration of human growth hormone.
Powell-Jackson J; Weller RO; Kennedy P; Preece MA; Whitcombe EM; Newsom-Davis J
Lancet; 1985 Aug; 2(8449):244-6. PubMed ID: 2862420
[TBL] [Abstract][Full Text] [Related]
31. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK.
Brandel JP; Preece M; Brown P; Croes E; Laplanche JL; Agid Y; Will R; Alpérovitch A
Lancet; 2003 Jul; 362(9378):128-30. PubMed ID: 12867116
[TBL] [Abstract][Full Text] [Related]
32. Serial EEG findings in sporadic and iatrogenic Creutzfeldt-Jakob disease.
Wieser HG; Schwarz U; Blättler T; Bernoulli C; Sitzler M; Stoeck K; Glatzel M
Clin Neurophysiol; 2004 Nov; 115(11):2467-78. PubMed ID: 15465434
[TBL] [Abstract][Full Text] [Related]
33. Creutzfeldt-Jakob disease. Infection of infancy or childhood?
Bergsholm P; Skre H; Mørk S
Eur Neurol; 1979; 18(2):73-8. PubMed ID: 378667
[TBL] [Abstract][Full Text] [Related]
34. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide.
Brandel JP; Peckeu L; Haïk S
Transfus Clin Biol; 2013 Sep; 20(4):395-7. PubMed ID: 23587616
[TBL] [Abstract][Full Text] [Related]
35. Iatrogenic Creutzfeldt-Jakob disease, final assessment.
Brown P; Brandel JP; Sato T; Nakamura Y; MacKenzie J; Will RG; Ladogana A; Pocchiari M; Leschek EW; Schonberger LB
Emerg Infect Dis; 2012 Jun; 18(6):901-7. PubMed ID: 22607808
[TBL] [Abstract][Full Text] [Related]
36. [Acquired Creutzfeldt-Jakob disease (CJD)--Kuru, iatrogenic CJD, variant CJD].
Sanjo N
Nihon Rinsho; 2007 Aug; 65(8):1438-45. PubMed ID: 17695281
[TBL] [Abstract][Full Text] [Related]
37. CT and MRI in iatrogenic and sporadic Creutzfeldt-Jakob disease: as far as imaging perceives.
García Santos JM; López Corbalán JA; Martínez-Lage JF; Sicilia Guillén J
Neuroradiology; 1996 Apr; 38(3):226-31. PubMed ID: 8741192
[TBL] [Abstract][Full Text] [Related]
38. Neuropathologic verification of Creutzfeldt-Jakob disease in the exhumed American recipient of human pituitary growth hormone: epidemiologic and pathogenetic implications.
Tintner R; Brown P; Hedley-Whyte ET; Rappaport EB; Piccardo CP; Gajdusek DC
Neurology; 1986 Jul; 36(7):932-6. PubMed ID: 3520381
[TBL] [Abstract][Full Text] [Related]
39. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation.
Uttley L; Carroll C; Wong R; Hilton DA; Stevenson M
Lancet Infect Dis; 2020 Jan; 20(1):e2-e10. PubMed ID: 31876504
[TBL] [Abstract][Full Text] [Related]
40. [Juvenile onset Creutzfeldt-Jakob disease with the history of neurosurgical operation].
Sato M; Murahashi M; Hara H; Jimi T; Wakayama Y
Rinsho Shinkeigaku; 2000 May; 40(5):428-32. PubMed ID: 11002723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
